Want to see CYTK full AI Analyst Report?
CYTK Stock Chart & Stats
$66.71
-$0.99(-2.05%)
At close: 4:00 PM EST
$66.71
-$0.99(-2.05%)
Day’s Range― - ―
52-Week Range$32.89 - $88.31
Previous CloseN/A
Volume107.14K
Average Volume (3M)2.26M
Market Cap
$9.98B
Enterprise Value$8.59K
Total Cash (Recent Filing)$818.55M
Total Debt (Recent Filing)$1.29B
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Jul 30, 2026EPS Estimate
-1.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.83
Shares Outstanding124,432,560
10 Day Avg. Volume1,803,070
30 Day Avg. Volume2,255,141
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)-11.56
Price to Sales (P/S)86.62
P/FCF Ratio-14.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$107.21Price Target Upside60.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-6.34
Revenue Forecast (FY)$112.55M
Bulls Say, Bears Say
Bulls Say
High Gross Margin & Improving RevenueSustained ~90% gross margins alongside TTM revenue growth (+20.2%) imply attractive unit economics for its muscle-targeted therapies. If commercial adoption scales, high gross margins allow revenue to meaningfully offset fixed R&D and launch costs, improving long-term profitability potential.
Early Commercial Launch TractionEarly uptake—initial product sales, growing prescriber base, REMS certifications and rising patient enrollments—reduces commercialization execution risk. Durable prescriber adoption and patient conversion rates support a multi-quarter revenue ramp and strengthen negotiating leverage with payers over time.
Material Capital Raise Improving RunwayA ~$760M equity raise materially expands financial flexibility and runway to fund launches, pivotal trials and regulatory activities. Reduced near-term refinancing pressure lets management execute commercial roll‑out and late‑stage programs without imminent dilution from urgent capital needs.
Bears Say
Elevated Leverage And Negative EquityHigh debt and negative equity signal an imbalanced capital structure that constrains financial flexibility. Persistent losses could force dilutive financing or costly debt restructurings, increasing long‑term financing risk and potentially limiting strategic optionality for pipeline investments.
Significant Cash Burn & Negative Free Cash FlowLarge ongoing operating and free cash outflows mean the business remains reliant on external capital to fund operations and trials. Even with recent raises, sustained negative FCF increases refinancing and dilution risk if commercial revenue growth and payer access lag expectations over the medium term.
Safety Observations In Acacia HCM ProgramNotable LVEF declines and a small number of serious heart‑failure events create regulatory and prescribing headwinds. Elevated safety surveillance or label restrictions could slow uptake, complicate payer coverage and increase monitoring costs, weighing on durable commercial penetration.
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $32.89 and its highest was $88.31 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $9.98B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Jul 30, 2026 which is in 9 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on May 05, 2026. The company reported -$1.67 earnings per share for the quarter, missing the consensus estimate of -$1.652 by -$0.018.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.63.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 124,432,560 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.67 in its last earnings report, missing expectations of -$1.652. Following the earnings report the stock price went down -2.919%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$107.21 (60.72% Upside)
$107.21 (60.72% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 766.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $17.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 12.6%
Last 30 Days ▲ 12.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.75%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK Stock 12 Month Forecast
Average Price Target
$107.21
▲(60.72% Upside)
Technical Analysis
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Nuvalent
―
Ownership Overview
0.79% Insiders
38.98% Mutual Funds
0.88% Other Institutional Investors
33.90% Public Companies and
Individual Investors